Similar articles

• Mitochondrial respiration inhibitor enhances the anti-tumor effect of high-dose ascorbic acid in castration-resistant prostate cancer.

  Qiu J, Yang T, Long Y, He P, Shen W, Zhang B, Shi X, Peng L, Li Z, Zhang X. Qiu J, et al. J Mol Med (Berl). 2023 Feb;101(1-2):125-138. doi: 10.1007/s00109-022-02273-5. Epub 2022 Dec 7. J Mol Med (Berl). 2023. PMID: 36478125
• Targeting the PI3K-AKT-mTOR Pathway in Castration Resistant Prostate Cancer: A Review Article.

  Cham J, Venkateswaran AR, Bhangoo M. Cham J, et al. Clin Genitourin Cancer. 2021 Dec;19(6):563.e1-563.e7. doi: 10.1016/j.clgc.2021.07.014. Epub 2021 Jul 31. Clin Genitourin Cancer. 2021. PMID: 34433523 Review.
• Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.

  Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M. Yasumizu Y, et al. J Urol. 2014 Jan;191(1):227-34. doi: 10.1016/j.juro.2013.07.101. Epub 2013 Aug 15. J Urol. 2014. PMID: 23954373
• Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.

  Bitting RL, Armstrong AJ. Bitting RL, et al. Endocr Relat Cancer. 2013 May 20;20(3):R83-99. doi: 10.1530/ERC-12-0394. Print 2013 Jun. Endocr Relat Cancer. 2013. PMID: 23456430 Review.
• Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.

  Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C. Kinkade CW, et al. J Clin Invest. 2008 Sep;118(9):3051-64. doi: 10.1172/JCI34764. J Clin Invest. 2008. PMID: 18725989 Free PMC article.